Trial Profile
A Randomized, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics of Single and 14 Day Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 1940029 (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 21 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 25 Jul 2014 Planned End Date changed from 1 Feb 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 25 Jul 2014 Planned primary completion date changed from 1 Feb 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.